SCHEMBL349293

SCHEMBL349293

CC(=O)Oc1c(C)cc(C(=O)O)cc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.50
HSD17B10 Q99714 3/20 0.50
ALDH1A1 P00352 3/20 0.50
HPGD P15428 2/20 0.50
GAA P10253 3/20 0.48
TSHR P16473 2/20 0.48
RAB9A P51151 1/20 0.48
HTT P42858 3/20 0.47
TP53 P04637 2/20 0.47
MAPT P10636 2/20 0.47
TPMT P51580 2/20 0.46
MAPK1 P28482 2/20 0.42
LMNA P02545 2/20 0.41
POLB P06746 1/20 0.41
HCAR1 Q9BXC0 1/20 0.41
BACE1 P56817 1/20 0.41
PKM P14618 2/20 0.39
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10790928 0.85 HTT (0.49) KDM4EHSD17B10ALDH1A1HPGDGAA
SCHEMBL8675250 0.85 KDM4E (0.49) KDM4EHSD17B10ALDH1A1HPGDGAA
SCHEMBL11338567 0.82 HTT (0.50) KDM4EHSD17B10ALDH1A1HPGDGAA
SCHEMBL22991582 0.82 KDM4E (0.46) KDM4EHSD17B10ALDH1A1HPGDGAA
SCHEMBL349440 0.82 KDM4E (0.46) KDM4EHSD17B10ALDH1A1HPGDGAA
SCHEMBL3156904 0.80 KDM4E (0.52) KDM4EHSD17B10ALDH1A1HPGDGAA
SCHEMBL641567 0.80 POLB (0.54) KDM4EHSD17B10ALDH1A1HPGDGAA
3,4,5-Triacetoxybenzoic Acid SCHEMBL716891 0.79 KDM4E (0.63) KDM4EHSD17B10ALDH1A1HPGDGAA
SCHEMBL29329332 0.79 KDM4E (0.58) KDM4EHSD17B10ALDH1A1HPGDGAA
SCHEMBL14700588 0.79 TUBB4A (0.50) KDM4EHSD17B10ALDH1A1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113748021-B Method for producing liquid crystal polyester processed product 本州化学工业株式会社 2024-07-05 CN claimed
US-12421452-B2 Method for producing liquid-crystal polyester processed product HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) 2025-09-23 US disclosed
CN-113748021-B Method for producing liquid crystal polyester processed product 本州化学工业株式会社 2024-07-05 CN disclosed
US-20240084196-A1 METHOD FOR PRODUCING LIQUID-CRYSTAL POLYESTER PROCESSED PRODUCT HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) 2024-03-14 US disclosed
US-11884864-B2 Method for producing liquid-crystal polyester processed product HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) 2024-01-30 US disclosed
US-20220204853-A1 METHOD FOR PRODUCING LIQUID-CRYSTAL POLYESTER PROCESSED PRODUCT HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) 2022-06-30 US disclosed
CN-113748021-A Method for producing liquid crystal polyester processed product 本州化学工业株式会社 2021-12-03 CN disclosed
US-20210361656-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES HEPALINK (HONG KONG) LIMITED (HK) 2021-11-25 US disclosed
US-20200352946-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. 2020-11-12 US disclosed
US-20180104245-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES HEPALINK (HONG KONG) LIMITED (HK) 2018-04-19 US disclosed
US-6087502-A COMPOUNDS FOR MARKING ANTIGENS OR ANTIBODIES RECEPTOR BINDING ASSAY MOCHIDA PHARMACEUTICALS CO., LTD. (JP) 2000-07-11 US disclosed
EP-0761652-A1 Acridinium compound having a plurality of luminescent groups and binding groups, and conjugate thereof MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1997-03-12 EP disclosed
EP-0472116-B1 Thienopyridine Derivatives, their production and use TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1996-01-31 EP disclosed
US-5256782-A For anticholesterol agents TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-10-26 US disclosed
US-5143919-A Acyl-CoA:cholesterol acyltransferase inhibitors; anticholesterol agents; TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1992-09-01 US disclosed
EP-0472116-A1 Thienopyridine Derivatives, their production and use Takeda Chemical Industries, Ltd. (JP) 1992-02-26 EP disclosed
US-4574066-A MELT POLYMERIZATION CATALYZED BY POTASSIUM ACETATE CELANESE CORPORATION (US) 1986-03-04 US disclosed
US-4398015-A POLYLACTONES; HIGH TENACITY FILAMENTS E. I. DU PONT DE NEMOURS & COMPANY (US) 1983-08-09 US disclosed
EP-0026608-A1 Aromatic polyester and filaments E.I. DU PONT DE NEMOURS AND COMPANY (US) 1981-04-08 EP disclosed
US-4232143-A Polyester which exhibits anisotropy in the melt containing p-oxybenzoyl units and 4,4'-dioxybenzophenone units or methyl and chloro derivatives thereof E. I. DU PONT DE NEMOURS AND COMPANY (US) 1980-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180104245-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, HDLBP, FABP3 KDM4E 4404/4885HSD17B10 254/4885ALDH1A1 548/4885
US-20210361656-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, HDLBP, FABP3 KDM4E 4404/4885HSD17B10 254/4885ALDH1A1 548/4885
US-20200352946-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, HDLBP, FABP3 KDM4E 4404/4885HSD17B10 254/4885ALDH1A1 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.